{"id":11979,"date":"2022-09-20T14:40:00","date_gmt":"2022-09-20T14:40:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3878284_AE78284_0"},"modified":"2022-09-20T14:40:00","modified_gmt":"2022-09-20T14:40:00","slug":"sirnaomics-to-present-latest-developments-on-sirna-therapeutics-for-cancer-and-galaheadtm-platform-programs-at-the-2nd-annual-oligonucleotide-therapeutics-and-delivery-conference","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=11979","title":{"rendered":"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference"},"content":{"rendered":"<div><img decoding=\"async\" src=\"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png\" class=\"ff-og-image-inserted\"><\/div>\n<div id=\"dvContent\" readability=\"63.527586206897\">\n<p>GAITHERSBURG, Md.&nbsp;and SUZHOU, <span class=\"xn-location\">China<\/span>, <span class=\"xn-chron\">Sept. 20, 2022<\/span> \/PRNewswire\/ &#8212;&nbsp;<b><a href=\"http:\/\/www.sirnaomics.com\/\" target=\"_blank\" rel=\"nofollow noopener\">Sirnaomics Ltd<\/a>. <\/b>(the &#8220;<b>Company<\/b>&#8221; or &#8220;<b>Sirnaomics<\/b>&#8220;, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead\u2122 platform and programs, at the 2<sup>nd<\/sup> Annual Oligonucleotide Therapeutics and Delivery Conference. The conference will take place on <span class=\"xn-chron\">September 21<\/span> and 22, 2022 with workshops on <span class=\"xn-chron\">September 20, 2022<\/span> at Copthorne Tara Hotel, <span class=\"xn-location\">London, UK<\/span>.<\/p>\n<p><b>Presentation Details<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Presentation Title<\/b>: Delivery of Novel siRNA Constructs for Treating Cancer<\/li>\n<li><b>Presenter<\/b>: Dr. <span class=\"xn-person\">David Evans<\/span>, Chief Scientific Officer, Sirnaomics<\/li>\n<li><b>Time\/Date<\/b>: 15:20 GMT on <span class=\"xn-chron\">Wednesday, September 21, 2022<\/span><\/li>\n<li><b>Presentation Topics<\/b>:<\/li>\n<ul type=\"disc\">\n<li>Creating novel siRNA constructs for cancer treatment<\/li>\n<li>Introduction to Sirnaomics&#8217; polypeptide nanoparticle delivery system (PNP-IT)<\/li>\n<li>Introduction to STP705, Sirnaomics&#8217; lead oncology siRNA therapeutic targeting TGF-\u03b21\/COX-2<\/li>\n<li>Discussion of novel siRNA therapeutics targeting other oncology indications<\/li>\n<\/ul>\n<li><b>Presentation Title<\/b>: GalAhead\u2122 Therapeutic Platform and Programs<\/li>\n<li><b>Presenter<\/b>: Dr. <span class=\"xn-person\">Jack Wei<\/span>, Senior Director, Sirnaomics<\/li>\n<li><b>Time\/Date<\/b>: 16:30 GMT on <span class=\"xn-chron\">Thursday, September 22, 2022<\/span><\/li>\n<li><b>Presentation Topics<\/b>:<\/li>\n<ul type=\"disc\">\n<li>Introduction to GalAhead\u2122, Sirnaomics&#8217; GalNAc-RNAi therapeutic platform<\/li>\n<li>Miniaturized RNAi (mxRNA) as a key technological component of the platform<\/li>\n<li>Validation of technology in vivo and in vitro<\/li>\n<li>Progress report on GalAhead\u2122-based programs<\/li>\n<\/ul>\n<\/ul>\n<p>For more information about Sirnaomics&#8217; presentation, please visit the event website at <a href=\"https:\/\/www.smgconferences.com\/pharmaceuticals\/uk\/conference\/oligonucleotide-discovery-delivery\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.smgconferences.com\/pharmaceuticals\/uk\/conference\/oligonucleotide-discovery-delivery<\/a>.<\/p>\n<p><b>About Sirnaomics<\/b>&nbsp;<\/p>\n<p>Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">the United States<\/span>, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at <a href=\"http:\/\/www.sirnaomics.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.sirnaomics.com<\/a>.<\/p>\n<p><b>CONTACT:<\/b>&nbsp;<\/p>\n<p><b>Investor&nbsp;Relations:<\/b><\/p>\n<p><span class=\"xn-person\">Nigel Yip<\/span>, MBA<\/p>\n<p>Chief Financial Officer, <span class=\"xn-location\">China<\/span>, Sirnaomics<\/p>\n<p>Email: <a href=\"mailto:NigelYip@sirnaomics.com\" target=\"_blank\" rel=\"nofollow noopener\">NigelYip@sirnaomics.com<\/a><\/p>\n<p><b>US Media Contact:<\/b><\/p>\n<p><span class=\"xn-person\">Alexis Feinberg<\/span><\/p>\n<p>Tel: +1 203 939 2225<\/p>\n<p>Email: <a href=\"mailto:Alexis.Feinberg@westwicke.com\" target=\"_blank\" rel=\"nofollow noopener\">Alexis.Feinberg@westwicke.com<\/a><\/p>\n<p><b>Asia Media Contact:<\/b><\/p>\n<p><span class=\"xn-person\">Bunny Lee<\/span><\/p>\n<p>Tel:&nbsp;+852 3150 6707<\/p>\n<p>Email: <a href=\"mailto:sirnaomics.hk@pordahavas.com\" target=\"_blank\" rel=\"nofollow noopener\">sirnaomics.hk@pordahavas.com<\/a><\/p>\n<\/p><\/div>\n<p>Source: Sirnaomics Ltd.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GAITHERSBURG, Md.&nbsp;and SUZHOU, China, Sept. 20, 2022 \/PRNewswire\/ &#8212;&nbsp;Sirnaomics Ltd. (the &#8220;Company&#8221; or &#8220;Sirnaomics&#8220;, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead\u2122 platform and programs, at the 2nd Annual [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-11979","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=11979\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference - My Blog\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md.&nbsp;and SUZHOU, China, Sept. 20, 2022 \/PRNewswire\/ &#8212;&nbsp;Sirnaomics Ltd. (the &#8220;Company&#8221; or &#8220;Sirnaomics&#8220;, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead\u2122 platform and programs, at the 2nd Annual [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=11979\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-20T14:40:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference\",\"datePublished\":\"2022-09-20T14:40:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979\"},\"wordCount\":370,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/en.prnasia.com\\\/prnasia.com-PC\\\/images\\\/logo-en-blue-in.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979\",\"name\":\"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/en.prnasia.com\\\/prnasia.com-PC\\\/images\\\/logo-en-blue-in.png\",\"datePublished\":\"2022-09-20T14:40:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979#primaryimage\",\"url\":\"https:\\\/\\\/en.prnasia.com\\\/prnasia.com-PC\\\/images\\\/logo-en-blue-in.png\",\"contentUrl\":\"https:\\\/\\\/en.prnasia.com\\\/prnasia.com-PC\\\/images\\\/logo-en-blue-in.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11979#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=11979","og_locale":"en_US","og_type":"article","og_title":"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference - My Blog","og_description":"GAITHERSBURG, Md.&nbsp;and SUZHOU, China, Sept. 20, 2022 \/PRNewswire\/ &#8212;&nbsp;Sirnaomics Ltd. (the &#8220;Company&#8221; or &#8220;Sirnaomics&#8220;, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead\u2122 platform and programs, at the 2nd Annual [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=11979","og_site_name":"My Blog","article_published_time":"2022-09-20T14:40:00+00:00","og_image":[{"url":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=11979#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11979"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference","datePublished":"2022-09-20T14:40:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11979"},"wordCount":370,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11979#primaryimage"},"thumbnailUrl":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=11979","url":"https:\/\/transmediavictoria.net.au\/?p=11979","name":"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11979#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11979#primaryimage"},"thumbnailUrl":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png","datePublished":"2022-09-20T14:40:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11979#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=11979"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=11979#primaryimage","url":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png","contentUrl":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=11979#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/11979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11979"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/11979\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}